GlassScriptPhysician profile
Sharon M Morgan
NPI 1629251343
$22,276.78
in general payments reported to CMS, 2019-2025
30 companies · $5,437 in 2025
The $5,437 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,108 · 2022: $2,478 · 2023: $8,622 · 2024: $4,632 · 2025: $5,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,187 · Travel and Lodging: $6,323 · Consulting Fee: $4,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,187.01 |
| Travel and Lodging | $6,322.65 |
| Consulting Fee | $4,181.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,401.81 | 2021-2025 | Symplicity G3, Corevalve Evolut R, Onyx Frontier |
| Abbott Laboratories | $2,458.68 | 2021-2025 | Cardiomems, Portico |
| Boston Scientific Corporation | $2,371.93 | 2021-2025 | Watchman, Watchman Flx, Watchman Access System |
| Cvrx, INC. | $1,271.00 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $677.21 | 2021-2024 | Saphnelo, Airsupra, Breztri |
| Impulse Dynamics (USA) INC. | $636.22 | 2022 | |
| Amgen INC. | $593.66 | 2022-2025 | Repatha, Uplizna, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $461.90 | 2022-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $415.77 | 2022-2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.13 | 2021-2023 | Jardiance |
| Abbvie INC. | $270.01 | 2022-2023 | |
| Glaxosmithkline, LLC. | $264.80 | 2023 | Arexvy |
| Tg Therapeutics, INC. | $170.90 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $146.85 | 2022 | |
| Janssen Biotech, INC. | $142.50 | 2024 | Tremfya, Stelara |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $140.70 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $138.34 | 2023 | Verquvo |
| Genentech USA, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Axsome Therapeutics, INC. | $124.59 | 2025 | Auvelity |
| Novo Nordisk INC | $121.83 | 2024 | Wegovy |
| Alnylam Pharmaceuticals INC. | $121.83 | 2025 | Amvuttra |
| Teva Pharmaceuticals USA, INC. | $116.32 | 2023 | Austedo Xr |
| Aimmune Therapeutics, INC. | $110.17 | 2025 | Zenpep |
| Nevro Corp. | $104.18 | 2022 | |
| Springworks Therapeutics, INC. | $103.53 | 2025 | Gomekli |
| Baxter Healthcare | $100.20 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Terumo Medical Corporation | $87.44 | 2025 | Angio-Seal, Heartrail |
| Sumitomo Pharma America, INC. | $78.01 | 2025 | Gemtesa |
| Pfizer INC. | $75.27 | 2024-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.